TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Brief Summary: To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
D: Arm Label: Treatment (temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: temsirolimus | Intervention Type: DRUG; Name: temsirolimus; Assigned to Arm(s): Treatment (temsirolimus)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Brief Summary: To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.


Options:
A: Arm Label: Combination navicixizumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Arm Label: Paclitaxel monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Xerna™ TME Panel | Arm Label: Navicixizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Intervention Type: DRUG; Name: navicixizumab; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy | Intervention Type: DEVICE; Name: Xerna™ TME Panel; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy, Paclitaxel monotherapy
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
D: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Brief Summary: To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
B: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
D: Arm Label: Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Triple-negative Breast Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: BRCA- positive Ovarian Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: ABT-888; Assigned to Arm(s): BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): BRCA- positive Ovarian Cancer: Cyclophosphamide Alone, BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Non-Hodgkin's: Cyclophosphamide Alone, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: Cyclophosphamide Alone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Brief Summary: To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.


Options:
A: Arm Label: olaparib + cediranib; Type: EXPERIMENTAL; Interventions: Drug: olaparib+cediranib combination therapy | Arm Label: durvalumab + olaparib; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + olaparib combination therapy | Arm Label: durvalumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + paclitaxel treatment | Arm Label: durvalumab +chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab +chemotherapy treatment | Intervention Type: DRUG; Name: olaparib+cediranib combination therapy; Assigned to Arm(s): olaparib + cediranib | Intervention Type: DRUG; Name: durvalumab + olaparib combination therapy; Assigned to Arm(s): durvalumab + olaparib | Intervention Type: DRUG; Name: durvalumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + tremelimumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + paclitaxel treatment; Assigned to Arm(s): durvalumab + tremelimumab + paclitaxel | Intervention Type: DRUG; Name: durvalumab +chemotherapy treatment; Assigned to Arm(s): durvalumab +chemotherapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1, 2, 3, 4
C: Intervention Type: DRUG; Name: PARP Inhibitors; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercising With Computers in Later Life (EXCELL) - Pilot and Feasibility Study of the Nintendo® WiiFit in Community-dwelling Fallers
Brief Summary: This is a pilot study to assess whether balance training with the Nintendo® Wii is comparable to a physiotherapist-led falls group in terms of improvement in balance. The acceptability of the Nintendo® Wii will also be assessed.


Options:
A: Arm Label: Standard Care; Type: N/A; Interventions: N/A | Arm Label: Intervention group; Type: N/A; Interventions: N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 3
C: Intervention Type: BEHAVIORAL; Name: game-based balance exercises; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: multifactorial intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multifactorial intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Brief Summary: This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.


Options:
A: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
B: Arm Label: TOBI (tobramycin inhaled solution)/Placebo; Type: EXPERIMENTAL; Interventions: Drug: TOBI, Drug: Placebo | Arm Label: Placebo/TOBI; Type: PLACEBO_COMPARATOR; Interventions: Drug: TOBI, Drug: Placebo | Intervention Type: DRUG; Name: TOBI; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo
C: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Brief Summary: This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.


Options:
A: Arm Label: TOBI (tobramycin inhaled solution)/Placebo; Type: EXPERIMENTAL; Interventions: Drug: TOBI, Drug: Placebo | Arm Label: Placebo/TOBI; Type: PLACEBO_COMPARATOR; Interventions: Drug: TOBI, Drug: Placebo | Intervention Type: DRUG; Name: TOBI; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo
B: Arm Label: Observational; Type: N/A; Interventions: N/A
C: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event
Brief Summary: Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acetyl-Salicylic Acid (ASA) and Clonidine, which are two medications, given individually for a short period before and after major surgeries may prevent major heart problems. The POISE-2 Trial is a large international study to test if ASA and Clonidine can prevent heart attacks and deaths from heart problems around the time of surgery.


Options:
A: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3
C: Intervention Type: DEVICE; Name: Renal Artery Stent with Protective Device/Drug; Assigned to Arm(s): N/A
D: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event
Brief Summary: Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acetyl-Salicylic Acid (ASA) and Clonidine, which are two medications, given individually for a short period before and after major surgeries may prevent major heart problems. The POISE-2 Trial is a large international study to test if ASA and Clonidine can prevent heart attacks and deaths from heart problems around the time of surgery.


Options:
A: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Placebo (PBO); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (PBO)
B: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): bupivacaine, saline

Answer: B